PG CL BMY 藥 美

Procter & Gamble stock rises on Q3 top and bottom-line beat, raised outlook

寶潔公司股票因第三季度業績優於華爾街預期而上漲，並提高了展望

Procter & Gamble Co.'s PG stock rose 1.2% premarket Friday after the consumer goods giant's fiscal third-quarter results topped Wall Street's top and bottom-line estimates. The company reported net income of $3.4 billion, or core earnings of $1.37 a share, up from net income of $3.36 billion, or core earnings of $1.33 a share in the same period last year. Analysts surveyed by FactSet were looking for earnings of $1.32 a share.

報導顯示，該公司在盈利和營收方面均超過華爾街預期，凈利潤為34億美元，或每股核心盈利1.37美元，高於去年同期的33.6億美元凈利潤或每股核心盈利1.33美元。FactSet的分析師預計每股收益為1.32美元。該公司股票在周五盤前上漲1.2%。

Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion

Bristol Myers Squibb Co. BMY announced Tuesday an agreement to buy radiopharmaceutical therapeutics company RayzeBio Inc. RYZB in a deal valued at $4.1 billion. Under terms of the deal, Bristol Myers will pay $62.50 in cash for each RayzeBio share outstanding, which represents a premium of 104.4% over Friday’s closing price of $30.57. RayzeBio’s stock was halted for new until 7:30 a.m. Eastern and Bristol Myers’ stock tacked on 0.2% in premarket trading. “This transaction enhances our increasingly diversified oncology portfolio by bringing a differentiated platform and pipeline, and further strengthens our growth opportunities...

ChatGPT：
Bristol Myers以超過100％的溢價，以價值41億美元的交易收購RayzeBio

Bristol Myers Squibb Co.（BMY）周二宣布同意以41億美元的價值收購放射性製劑治療公司RayzeBio Inc.（RYZB）。根據交易條款，Bristol Myers將支付每股RayzeBio的現金62.50美元，這相當於每股30.57美元的上週五收盤價的104.4％的溢價。RayzeBio的股票在東部時間上午7:30之前停牌，Bristol Myers的股票在盤前交易中上漲0.2％。“這筆交易通過引入一個差異化的平台和管道，進一步增強我們日益多元化的腫瘤學組合，並進一步加強我們的增長機會......"

Google自動翻譯或是ChatGPT常常把$ 1 billion 當成一百億美元，依美國人的用法應該只是10億美元罷了！

啊！沒double check，
想不到ChatGPT也會出現這種低級錯誤
謝謝James桑指正
已改正